


TECH CENTER 1600/290



#13/K.T. 2/26 PATENT ELECT.

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Paolo Renzi

Group No.: 1635

Application No.: Filed:

Examiner: Karen A. Lacourciere

For:

09/719,737 ANTISENSE OLIGONUCLEOTIDES FOR TREATING ATOPIC DISEASES AND

NEOPLASTIC CELL PROLIFERATION

### CERTIFICATE OF MAILING (37 C.F.R. SECTION 1.8(a))

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the united States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

February 14, 2003

Date

Nicole M. Gignac

(type or print name of person mailing paper)

Signature of person mailing

**Assistant Commissioner for Patents** Washington, D.C. 20231

## RESPONSE TO RESTRICTION REQUIREMENT / AMENDMENT

In response to the Restriction Requirement of January 15, 2003 in the above-identified application, Applicant elects Group IV (claims 42-45, 50-55 and 68-72), with traverse drawn to a composition comprising an antisense oligonucleotide targeted to a common subunit of IL-3, IL-5 and GM-CSF receptors (SEQ ID NO:9) and an oligonucleotide targeted to a nucleic acid encoding a CCR3 receptor (SEQ ID NO:18). The specific species of séquences are identified in parenthesis by their respective SEQ ID Nos.

#### FEE AUTHORIZATION

Should any fees be associated with the submission be required, the Commissioner is authorized to such deficiencies to our Deposit Account No. 50-0850. Any overpayments should be credited to said

Deposit Account.

Date: February 14, 2003

Respectfully submitted,

Customer No.: 26770

David S. Resnick (Reg. No. 34,235)

NIXON PEABODY LLP

101 Federal Street

Boston, MA 02110 Tel: (617) 345-6057

Fax: (617) 345-1300



Ç.

tioner's Docket No. 701826-051150

**PATENT** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Paoio Renzi

Application No.:

Group No.: 1635 09/719,737

Filed:

Examiner: Karen A. Lacourciere ANTISENSE OLIGONUCLEOTIDES FOR TREATING ATOPIC DISEASES

For:

AND NEOPLASTIC CELL PROLIFERATION

# CERTIFICATE OF MAILING/TRANSMISSION (37 C.F.R. § 1.8(a) and 1.10)

I hereby certify that this correspondence:

- 1. Transmittal Form (1 pg.);
- 2. Restriction Requirement (1 pg..);
- 3. Return Receipt Postcard;

is on the date shown below being:

#### **MAILING**

X deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: February 14, 2003

**FACSIMILE** 

transmitted by facsimile to the Patent and Trademark Office.

Nicole M. Gignac

(type or print name of person certifying)

2003

TRANSMITTAL FORM  (to be used for all correspondence after initial filing)  Total Number of Pages in This Submission  EN	ons are required to respond to a collection	After Allowance Communication to Group  Appeal Communication to B
Certified Copy of Priority Document(s)  Response to Missing Parts/ Incomplete Application  Response to Missing Parts under 37 CFR 1.52 or 1.53	Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Add Terminal Disclaimer Request for Refund CD, Number of CD(s) emarks  Commissioner is authorized to the NIXON PEABODY L	Appeal Communication to Gentle (Appeal Notice, Brief, Reply Brief)  Proprietary Information  Status Letter  Other Enclosure(s) (please Identify below): Certificate of Mailing; Return Receipt Postcard.
1.1.(D)	JUL, TOT TOUS	.M. Valtz (Reg. 10. 17,

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date:

Typed or printed

Nicole M. Gignac

Date

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including application, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the gathering, preparing, and submitting the complete displayed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the gathering preparing application of the USPTO. Time will vary depending upon the individual case. Any comments on the gathering preparing application form to the USPTO. Time will vary depending upon the individual case. Any comments on the gathering preparing application form to the USPTO. Time will vary depending upon the individual case. Any comments on the gathering preparing application form to the USPTO. Time will vary depending upon the individual case. Any comments of t